TY - JOUR
T1 - NKT cells stimulated by long fatty acyl chain sulfatides significantly reduce the incidence of type 1 diabetes in nonobese diabetic mice [corrected]
AU - Subramanian, Lakshmimathy
AU - Blumenfeld, Hartley
AU - Tohn, Robert
AU - Ly, Dalam
AU - Aguilera, Carlos
AU - Maricic, Igor
AU - Mansson, Jan-Eric
AU - Buschard, Karsten
AU - Kumar, Vipin
AU - Delovitch, Terry L
PY - 2012
Y1 - 2012
N2 - Sulfatide-reactive type II NKT cells have been shown to regulate autoimmunity and anti-tumor immunity. Although, two major isoforms of sulfatide, C16:0 and C24:0, are enriched in the pancreas, their relative role in autoimmune diabetes is not known. Here, we report that sulfatide/CD1d-tetramer(+) cells accumulate in the draining pancreatic lymph nodes, and that treatment of NOD mice with sulfatide or C24:0 was more efficient than C16:0 in stimulating the NKT cell-mediated transfer of a delay in onset from T1D into NOD.Scid recipients. Using NOD.CD1d(-/-) mice, we show that this delay of T1D is CD1d-dependent. Interestingly, the latter delay or protection from T1D is associated with the enhanced secretion of IL-10 rather than IFN-g by C24:0-treated CD4(+) T cells and the deviation of the islet-reactive diabetogenic T cell response. Both C16:0 and C24:0 sulfatide isoforms are unable to activate and expand type I iNKT cells. Collectively, these data suggest that C24:0 stimulated type II NKT cells may regulate protection from T1D by activating DCs to secrete IL-10 and suppress the activation and expansion of type I iNKT cells and diabetogenic T cells. Our results raise the possibility that C24:0 may be used therapeutically to delay the onset and protect from T1D in humans.
AB - Sulfatide-reactive type II NKT cells have been shown to regulate autoimmunity and anti-tumor immunity. Although, two major isoforms of sulfatide, C16:0 and C24:0, are enriched in the pancreas, their relative role in autoimmune diabetes is not known. Here, we report that sulfatide/CD1d-tetramer(+) cells accumulate in the draining pancreatic lymph nodes, and that treatment of NOD mice with sulfatide or C24:0 was more efficient than C16:0 in stimulating the NKT cell-mediated transfer of a delay in onset from T1D into NOD.Scid recipients. Using NOD.CD1d(-/-) mice, we show that this delay of T1D is CD1d-dependent. Interestingly, the latter delay or protection from T1D is associated with the enhanced secretion of IL-10 rather than IFN-g by C24:0-treated CD4(+) T cells and the deviation of the islet-reactive diabetogenic T cell response. Both C16:0 and C24:0 sulfatide isoforms are unable to activate and expand type I iNKT cells. Collectively, these data suggest that C24:0 stimulated type II NKT cells may regulate protection from T1D by activating DCs to secrete IL-10 and suppress the activation and expansion of type I iNKT cells and diabetogenic T cells. Our results raise the possibility that C24:0 may be used therapeutically to delay the onset and protect from T1D in humans.
KW - Animals
KW - Antigens, CD1d/genetics
KW - CD4-Positive T-Lymphocytes/metabolism
KW - Diabetes Mellitus, Type 1/prevention & control
KW - Flow Cytometry
KW - Interleukin-10/metabolism
KW - Interleukin-2/metabolism
KW - Interleukin-4/metabolism
KW - Lymph Nodes/cytology
KW - Mice
KW - Mice, Inbred NOD/metabolism
KW - Mice, Knockout
KW - Natural Killer T-Cells/metabolism
KW - Pancreas/cytology
KW - Structure-Activity Relationship
KW - Sulfoglycosphingolipids/pharmacology
U2 - 10.1371/journal.pone.0037771
DO - 10.1371/journal.pone.0037771
M3 - Journal article
C2 - 22649557
SN - 1932-6203
VL - 7
SP - e37771
JO - PLoS One
JF - PLoS One
IS - 5
ER -